Key result
SCORE-CVD-MI algorithm yields superior agreement with trial-reported MI over conventional code lists.
Why the study?
Cardiovascular safety monitoring in oncology trials is critical, and the feasibility of using health system data with phenotyping algorithms for myocardial infarction ascertainment was unclear.
Does the SCORE-CVD-MI phenotyping algorithm accurately ascertain myocardial infarction events in prostate cancer clinical trial participants using routine health system data?
Observational (n=6,901)
Yes
Does the SCORE-CVD-MI phenotyping algorithm accurately ascertain myocardial infarction events in prostate cancer clinical trial participants using routine health system data?
The SCORE-CVD-MI phenotyping algorithm applied to routine health system data accurately ascertains myocardial infarction events, offering a reliable method for cardiovascular safety monitoring in oncology trials.
Answers are grounded in this paper and cite their sources.
SCVD may enhance MI ascertainment from routine data in oncology trials; extends phenotyping validation but leaves broader adoption open pending prospective studies.
Background Cardiovascular safety is critical in oncology trials. Health system data (HSD) can facilitate event detection while minimising site burden. Purpose We aimed to evaluate the feasibility of ascertaining myocardial infarction (MI) in a prostate cancer clinical trial using HSD and a recently developed phenotyping algorithm. Methods Participants from a large prostate cancer trial were linked to Hospital Episode Statistics – Admitted Patient Care (HES-APC), which contains all NHS inpatient admissions in England. MI events were identified from HES-APC using two approaches: conventional code lists (cHES) and the SCORE-CVD-MI phenotyping algorithm (SCVD). Agreement with trial-reported MI was assessed. Results A total of 6,901 trial participants with 44,405 HES-APC episodes were included. Over a median follow-up of 21.2 months (IQR 5.7-65.9), 91 MIs were reported in 90 (1.3%) trial participants. SCVD identified 84 (92.3%) of these events, and cHES 83 (91.2%). Agreement between SCVD and the trial was moderate-to-strong (kappa: 0.79, 95% CI: 0.77 to 0.82), and higher than between cHES and the trial (kappa: 0.72, 95% CI: 0.70 to 0.75) (p=0.001). Sensitivity and specificity of SCVD were 0.99 (95% Credible Interval 0.99-0.99) and 0.95 (95% Credible Interval 0.88-0.99). Time-to-first-event analysis were comparable between SCVD and trial [HRpatient-strata (95% CI): 1.23 (0.93-1.64), p = 0.148]. Conclusions Identification of MI admissions using HES-APC was feasible and accurate in a prostate cancer trial. The SCVD phenotyping algorithm outperformed the conventional approach, offering a promising and reproducible method for cardiovascular safety monitoring in oncology trials.
No takes yet. Share an insight, caveat, or question.
Manzanares et al. (2026) conducted an observational in Prostate cancer (n=6,901). SCORE-CVD-MI phenotyping algorithm (SCVD) vs. Conventional code lists (cHES) was evaluated on Agreement with trial-reported myocardial infarction (kappa) (p=0.001). The SCORE-CVD-MI phenotyping algorithm demonstrated higher agreement with trial-reported myocardial infarction than conventional code lists.
Synapse has enriched 10 related papers. Consider them for comparative context: